EcoDrugPlus

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSMMSG00000002994
Gene Symbol: GIPR
1 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSMMSG00000007945
Gene Symbol: GLP1R
1 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSMMSG00000018578
Gene Symbol: GLP2R
1 Cross references
205 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSMMSG00000023503
Gene Symbol: GCGR
1 Cross references
183 Possible Orthologues:

Glucokinase

Ensembl ID : ENSMMSG00000010554
Gene Symbol: GCK
1 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSMMSG00000007999
Gene Symbol: GBA1
1 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSMMSG00000003129
Gene Symbol: GRIA1
1 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSMMSG00000005571
Gene Symbol: GRIA2
1 Cross references
320 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSMMSG00000005959
Gene Symbol: GRIA3
1 Cross references
318 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSMMSG00000008872
Gene Symbol: GRIA4
1 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSMMSG00000012663
Gene Symbol: GRIN2A
1 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSMMSG00000021047
Gene Symbol: GRIN2B
1 Cross references
330 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).